The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients' outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature and composed a framework of the best recommendations for optimal infection control...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
Treatment of myelodysplastic syndromes (MDS) has evolved to encompass a broad spectrum of therapies ...
The improvement in supportive care and the introduction of new therapeutic agents, including lenalid...
The improvement in supportive care and the introduction of new therapeutic agents, including lenalid...
OBJECTIVES: Infections are a major cause of morbidity and mortality in patients with myelodysplastic...
Infections remain a significant problem in myelodysplastic syndromes (MDS) in treated as well in non...
The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors...
The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This s...
Background and Objectives. Novel therapeutic agents and strategies have been introduced into the man...
BACKGROUND AND OBJECTIVES: Novel therapeutic agents and strategies have been introduced into the man...
OBJECTIVES: Infections are a major cause of morbidity and mortality in patients with myelodysplastic...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
Treatment of myelodysplastic syndromes (MDS) has evolved to encompass a broad spectrum of therapies ...
The improvement in supportive care and the introduction of new therapeutic agents, including lenalid...
The improvement in supportive care and the introduction of new therapeutic agents, including lenalid...
OBJECTIVES: Infections are a major cause of morbidity and mortality in patients with myelodysplastic...
Infections remain a significant problem in myelodysplastic syndromes (MDS) in treated as well in non...
The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors...
The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This s...
Background and Objectives. Novel therapeutic agents and strategies have been introduced into the man...
BACKGROUND AND OBJECTIVES: Novel therapeutic agents and strategies have been introduced into the man...
OBJECTIVES: Infections are a major cause of morbidity and mortality in patients with myelodysplastic...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
Treatment of myelodysplastic syndromes (MDS) has evolved to encompass a broad spectrum of therapies ...